Related Experiment Video
Updated: Aug 11, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer
A Hugh Mostafid1, Raj G N Rajkumar, Alistair B Stewart
1Department of Urology, North Hampshire Hospital, Basingstoke, Hants, UK. mostafid@globalnet.co.uk
Objective:
To assess the feasibility and safety of administering intravesical mitomycin C in theatre immediately after transurethral resection of bladder tumour (TURBT).
Patients And Methods:
A protocol was developed to allow the safe administration of mitomycin C in theatre immediately after TURBT. Over a 32-month period all patients not excluded by the protocol were given mitomycin C in theatre after TURBT, and any adverse events reported.
Results:
In all, 177 instillations were carried out; there were two minor patient-related complications, and no staff-related adverse events.
Conclusion:
The immediate administration of mitomycin C in theatre after TURBT is feasible and safe for patients and staff. It provides the earliest and surest prophylaxis against tumour cell re-implantation at TURBT.